Table 2.
Univariable and multivariable Cox‐proportional hazard model for overall survival in BCLC very-early stage hepatocellular carcinoma patients
| Characteristics | Univariate Cox regression analyses | Multivariate Cox regression analyses | ||
|---|---|---|---|---|
| Unadjusted HR (95% CI) | P-value | Adjusted HR (95% CI) | P-value | |
| Treatment type (SR vs. RFA) | 2.58 (1.56–4.25) | < 0.001 | 1.75 (1.08–3.11) | 0.046 |
| Male | 1.20 (0.71–2.04) | 0.501 | ||
| Age (≥ 60y vs, < 60y) | 0.74 (0.46–1.19) | 0.219 | ||
| BMI (≥ 24 kg/m2 vs. < 24 kg/m2) | 1.06 (0.66–1.71) | 0.808 | ||
| Alcohol use | 0.71 (0.43–1.19) | 0.196 | ||
| HBV | 1.58 (0.96–2.59) | 0.073 | ||
| HCV | 0.74 (0.46–1.19) | 0.212 | ||
| Child‐Pugh class A | 2.60 (1.19–5.70) | 0.017 | 1.21 (0.46–3.17) | 0.697 |
| Cirrhosis | 0.52 (0.31–0.88) | 0.015 | 0.90 (0.50–1.60) | 0.709 |
| Ascites | 0.39 (0.20–0.76) | 0.006 | 0.56 (0.28–1.13) | 0.104 |
| Total bilirubin (≥ 1.3 mg/dL vs. < 1.3 mg/dL) | 0.33 (0.20–0.54) | < 0.001 | 0.52 (0.28–0.95) | 0.034 |
| Albumin (≥ 3.5 g/dL vs. < 3.5 g/dL) | 2.55 (1.33–4.87) | 0.005 | 1.59 (0.74–3.38) | 0.232 |
| ALBI grade 1 vs. 2/3 | 1.91 (1.04–3.52) | 0.036 | 1.10 (0.52–2.35) | 0.798 |
| AFP (≥ 200 ng/ml vs. < 200 ng/ml) | 0.56 (0.31–1.00) | 0.051 | ||
| Tumor size (≥ 1.8 cm vs. < 1.8 cm) | 0.68 (0.41–1.13) | 0.137 | ||
| Tumor recurrence | 0.45 (0.28–0.74) | 0.002 | 0.46 (0.28–0.78) | 0.006 |
CI: Conference Incidence; SR: Surgical resection; BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALBI: Albumin- bilirubin; AFP: Alpha-fetoprotein;